NCT03012607View on ClinicalTrials.gov

Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Hiv
Interventions
DRUG

Truvada

Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)

Trial Locations (1)

Unknown

Sanpatong Hospital, Chiang Mai

All Listed Sponsors
collaborator

Chiang Mai University

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Washington

OTHER

NCT03012607 - Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy | Biotech Hunter | Biotech Hunter